EMEA-003300-PIP01-22 - paediatric investigation plan
Zigakibart
PIPHuman
Key facts
- Active Substance
- Zigakibart
- Therapeutic area
- Renal and urinary disorders
- Decision number
- P/0033/2024
- PIP number
- EMEA-003300-PIP01-22
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of primary IgA nephropathy
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Novartis Europharm Limited
Email: paediatric.enquiries@novartis.com- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date